samedan logo
home > pmps > spring 2013 > strategies for success
Pharmaceutical Manufacturing and Packing Sourcer

Strategies for Success

I have recently received copies of two books which will be of great interest to those involved in manufacturing and packaging of pharmaceuticals. A Guide to Cleaning and Disinfecting Cleanrooms is a comprehensive handbook aimed at those working within the pharmaceutical and healthcare sectors, detailing the different types of disinfectants and their mode of action. It explains the problems of microbial destruction and resistance, and introduces cleaning techniques and the latest safety regulations. The book also discusses the application of cleaning within healthcare and pharmaceutical environments within the context of current national and international standards. The editor, Dr Tim Sandle, has over 20 years’ experience as a pharmaceutical microbiologist. Although the authors of the various chapters are from the UK, nonetheless the book has an international flavour and is sponsored by the well-renowned German disinfectant manufacturers Schulke and Mayr from Hamburg.

Disinfection in the workplace – be it for the pharmaceutical industry, within hospitals, or even the catering sector – is a subject of great current importance. The book calls itself a handbook and proclaims that it is not a book intended to sit on a shelf and gather dust, but that it should be read and discussed by those whose business it is to keep cleanrooms, hospitals, and the hands of their staff clean. It could well become a classic of its time and can certainly form the basis of standard operating procedures throughout the industry. It is thoroughly recommended.

A Guide to Cleaning and Disinfecting Cleanrooms by Dr Tim Sandle (ed) is published by Grosvenor House Publishing. ISBN: 978-1-78148-768-6

Developing and Sustaining Excellent Packaging Labelling and Artwork Capabilities is again a practical guide for those involved in these topics. Both the authors know their subject inside out, having spent many years in global packaging design operations at GlaxoSmithKline before founding the consulting company that published this book. The guide discusses the importance of artwork capabilities in delivering today’s business strategy and the causes of artwork errors. There is detailed discussion on many of the elements which go into the overall artwork capability. These include business processes, education and training, competence assessment, organisation design, technology and outsourcing. When debating any fast-moving topic it is always important that improvements should be sustained, and this book goes into some detail about how this can be achieved in the packaging field.

The authors note that in addition to making a product attractive and marketable to the eventual consumer, packaging and artwork also represent a significant risk in terms of regulatory compliance. Indeed, there are many business challenges which face the pharmaceutical and healthcare sectors, particularly at this time of economic challenge. Companies need to deliver as many new product variants in different markets as quickly as possible, while at the same time enhancing their reputation with regulators and governments, the public and other stakeholders. The book argues that creating an artwork management strategy is critical to delivering this business plan, noting that it is a complex endeavour and involves numerous internal functions in many countries of the world. The authors claim that excellence is achievable, having already accomplished this themselves in one company, and propose that this book is a significant contribution to achieving such success.

Developing and Sustaining Excellent Packaging Labelling and Artwork Capabilities by Stephen McIndoe and Andrew Love is published by ecademyPRESS. ISBN: 978-1-908746-16-0

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

Print this page
Send to a friend
Privacy statement
News and Press Releases

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

SAN DIEGO, Calif. & CAMBRIDGE, England, May 20, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT). Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections.
More info >>

White Papers
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement